|
|
Dermatologists' Case
Files:
Managing Premalignant Skin Disorders
A supplement to Skin & Allergy
News, supported by a restricted educational grant from 3M
Pharmaceuticals and designated by the American Academy of
Dermatology (AAD) for AAD continuing medical educational
(CME) credit.
Topics
- Management of Actinic Keratosis and Malignant Skin Lesions
- Management of Actinic Keratosis
- Challenges of Lentigo Maligna
- Topical Therapy for Cutaneous Metastatic Melanoma
|
Faculty
Christopher B. Zachary, MBBS, FRCP
Professor and Chair
Department of Dermatology
University of California at Irvine
Mitchell E. Stashower, MD
The Clinical Skin Center of Northern Virginia, Fairfax
Assistant Professor of Dermatology
Uniformed Services University of Health Sciences
Bethesda, Md.
M. Shane Chapman, MD
Associate Professor of Medicine (Dermatology)
Dartmouth-Hitchcock Medical Center
Lebanon, N.H.
|
Back to top  |
Faculty
Disclosures
The faculty of this CME activity
disclose the following:
| Faculty Member |
|
|
|
Christopher B. Zachary, MBBS, FRCP
MD |
Dr. Zachary has received funding for clinical grants from and is a speaker for Candela Laser GmbH, Iridex Corporation, Reliant Pharmaceuticals, and Sciton, Inc. He is also a consultant to Ferndale Laboratories, Inc., and SkinMedica.
|
|
Mitchell E. Stashower, MD
|
Dr. Stashower is a speaker, consultant, and investigator for 3M.
|
|
M. Shane Chapman, MD
|
Dr. Chapman has received funding for clinical grants from and is a consultant to 3M Pharmaceuticals. He discusses the unlabeled use of imiquimod for the treatment of lentigo maligna.
|
| |
| Back to top |
Target Audience
This educational activity has been developed for dermatologists and other health care providers involved in the care of patients who present with skin lesions that have malignant potential.
(IRM) therapy may
be considered. |
Educational
Needs
A widespread lax approach to prevention of sun-induced skin problems continues to send millions of patients to dermatologists’ offices for evaluation and treatment of premalignant and malignant skin lesions. Actinic keratosis alone accounts for 47 million dermatologist office visits annually. Surgical and destructive or abrasive therapies represent the primary approach to treatment of premalignant and malignant skin lesions. Topical agents have had only a minor role in the management of these lesions, aside from topical 5-fluorouracil, which many patients find difficult to tolerate. Development of effective, better-tolerated, topical agents potentially could have a major impact on the approach to management of conditions such as actinic keratosis, lentigo maligna, and cutaneous metastatic melanoma.
|
| Back to top |
Learning Objectives
Upon completion of this educational activity, participants should be able to:
· Recognize
common skin lesions that have malignant
potential.
.
· Describe
current approaches to treatment of premalignant and
malignant skin lesions
.
· Understand
the role of nonsurgical, nondestructive
therapies.
· Appreciate the therapeutic potential of effective, well-tolerated topical agents for treatment of premalignant and malignant skin lesions.
|
| Back to top |
CME
Recognition
This Skin & Allergy News
supplement is recognized by the American Academy
of Dermatology (AAD) for 1 hour of AAD Category 1 CME credit
and may be used toward the American Academy of Dermatology’s
Continuing Medical Education Award.
This program was developed in
accordance with the Accreditation Council for Continuing
Medical Education guidelines.
Term
of Approval: September 2006—August 31, 2007
Copyright
© 2006 Elsevier Inc.
|